Bariatric Surgery Reduces Cardiovascular Risk More Than GLP-1 Drugs in Obesity and Diabetes
Metabolic and bariatric surgery provides greater cardiovascular protection than GLP-1 receptor agonists in individuals with obesity and type 2 diabetes, with a 52% relative risk reduction in major adverse cardiac events and all-cause mortality.
Metabolic and bariatric surgery (MBS) offers greater cardiovascular protection than glucagon-like peptide-1 (GLP-1) receptor agonists in individuals with obesity and type 2 diabetes, a 2026 systematic review and meta-analysis has found. Surgery was more favourable for both major adverse cardiovascular events (MACE) and all-cause mortality outcomes.
Nearly 20,000 individuals with obesity and type 2 diabetes were included in analysis. MBS was associated with a significant reduction in the risk of MACE and all-cause mortality compared with GLP-1 receptor agonist therapy, with a relative risk reduction of 52%. Analysis found that MBS produces greater sustained weight loss compared to GLP-1 receptor agonist therapy.
Observed benefits of MBS extended beyond glycaemic control and weight loss. Researchers suggested this reflected the multifactorial impact of surgery on metabolic and cardiovascular risk. While both treatment pathways offer substantial clinical benefit, MBS provided a more pronounced and durable risk reduction. This was particularly apparent in patients with longstanding diabetes and higher cardiovascular risk.
MBS has emerged as a highly effective intervention, leading to remission of diabetes in approximately 31% to 56% of patients. GLP-1 receptor agonist therapy is an established treatment option that improves metabolic parameters and reduces cardiovascular mortality and hospitalisation rates.
GLP-1 receptor agonists are effective in reducing cardiovascular events and improving metabolic parameters, but (particularly long-term) patient benefit appears greater with surgical intervention. Researchers emphasised that GLP-1 receptor agonist therapy remains essential for patients who are ineligible for surgery or seeking non-surgical intervention.
Recent meta-analyses and large-scale cohort studies have provided robust supporting evidence that MBS is more favourable than GLP-1 receptor agonists in reducing both MACE and all-cause mortality in individuals with obesity and type 2 diabetes. The review compared the effects of MBS and GLP-1 receptor agonists on all-cause mortality and nonfatal MACE in individuals with obesity and type 2 diabetes.